Expression Therapeutics to present at BIO CEO & Investor Conference 2022
ATLANTE, February 8, 2022 /PRNewswire/ — Expression Therapeutics, Inc. today announced that Chief Executive Officer, Dr. Mohan Raowas selected to present at the BIO CEO & Investor Conference in New York City from February 14-16 and participate in one-on-one meetings with investors.
Start February 14tha pre-recorded presentation will be available for on-demand viewing on the BIO CEO & Investor Conference portal for registered attendees and the investor slideshow is available upon request from Kim approaches at Expression Therapeutics. For more information, please see https://www.bio.org/events/bio-ceo-investor-conference.
About Expression Therapeutics, Inc.
Expression Therapeutics, Inc. is a fully integrated clinical-stage cell and gene therapy company developing novel therapies for oncology and hematology. The Company’s oncology platform is based on a proprietary signaling-free chimeric antigen receptor technology that enhances the targeting ability of gamma delta T cells and alleviates problems with long-term T cell ablation and tonic signaling to develop allogeneic cell therapies for neuroblastoma, T-cell leukemia and lymphoma and acute myeloid leukemia. Expression’s scientific breakthroughs in transgene bioengineering and protein engineering allow it to optimize its gene therapies for bleeding disorders. Expression also has a scalable, state-of-the-art 43,000 square foot manufacturing facility capable of producing cGMP viral vectors and cell therapy products to accelerate the development of the company’s clinical programs.
View original content: https://www.prnewswire.com/news-releases/expression-therapeutics-to-present-at-the-2022-bio-ceo–investor-conference-301477632.html
SOURCE Expression Therapeutics